

Yu-Jung Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1850372/publications.pdf>

Version: 2024-02-01

39
papers

715
citations

567281

15
h-index

580821

25
g-index

39
all docs

39
docs citations

39
times ranked

1082
citing authors

#	ARTICLE	IF	CITATIONS
1	Discontinuation of Long-Term Opioid Therapy in Patients With Versus Without Dementia. <i>American Journal of Preventive Medicine</i> , 2022, 62, 270-274.	3.0	3
2	Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults. <i>American Journal of Preventive Medicine</i> , 2022, 62, 519-528.	3.0	5
3	Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003921.	8.4	8
4	Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study. <i>PLoS Medicine</i> , 2022, 19, e1003947.	8.4	7
5	Perioperative Use of Gabapentinoids and Risk for Postoperative Long-Term Opioid Use in Older Adults Undergoing Total Knee or Hip Arthroplasty. <i>Journal of Arthroplasty</i> , 2022, 37, 2149-2157.e3.	3.1	2
6	Utilization Patterns of Skeletal Muscle Relaxants Among Commercially Insured Adults in the United States from 2006 to 2018. <i>Pain Medicine</i> , 2021, 22, 2153-2161.	1.9	9
7	Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 78.	6.2	9
8	Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Residents With Dementia. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2079-2086.e5.	2.5	17
9	Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home. <i>Aging and Mental Health</i> , 2021, 25, 1897-1902.	2.8	4
10	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. <i>Drug Safety</i> , 2020, 43, 329-338.	3.2	15
11	Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1414-1422.	1.9	14
12	Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 81-89.	4.7	33
13	Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: An interrupted time series analysis. <i>Drug and Alcohol Dependence</i> , 2019, 202, 172-177.	3.2	10
14	Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107600.	3.2	8
15	Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration. <i>Pharmacotherapy</i> , 2019, 39, 1042-1052.	2.6	5
16	Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study. <i>PLoS Medicine</i> , 2019, 16, e1002941.	8.4	21
17	Body weight, frailty, and chronic pain in older adults: a cross-sectional study. <i>BMC Geriatrics</i> , 2019, 19, 143.	2.7	39
18	Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1417-1427.	1.9	89

#	ARTICLE	IF	CITATIONS
19	Performance of the Centers for Medicare & Medicaid Servicesâ€™ Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 609.	7.4	6
20	Clinical utility and perils of prescription drug monitoring programâ€‘based alert systems. <i>Pain</i> , 2018, 159, 804-805.	4.2	1
21	The association of antidepressant treatment with COPD maintenance medication use and adherence in a comorbid Medicare population: A longitudinal cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, e212-e220.	2.7	17
22	Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study. <i>Otology and Neurotology</i> , 2018, 39, 957-963.	1.3	8
23	Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder. <i>JAMA Network Open</i> , 2018, 1, e181152.	5.9	22
24	Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 833-839.	1.3	5
25	Adherence and healthcare utilization among older adults with COPD and depression. <i>Respiratory Medicine</i> , 2017, 129, 53-58.	2.9	22
26	Mortality Risk of Antipsychotic Dose and Duration in Nursing Home Residents with Chronic or Acute Indications. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 973-980.	2.6	12
27	Algorithm for Identifying Nursing Home Days Using Medicare Claims and Minimum Data Set Assessment Data. <i>Medical Care</i> , 2016, 54, e73-e77.	2.4	36
28	Fall and Fracture Risk in Nursing Home Residents With Moderate-to-Severe Behavioral Symptoms of Alzheimerâ€™s Disease and Related Dementias Initiating Antidepressants or Antipsychotics. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 72, glw095.	3.6	8
29	Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1497-1504.	3.2	40
30	Response to Lapane and Colleagues. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 834-834.	2.6	0
31	Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1757-1765.	2.6	13
32	Relationships between antiparkinson medication nonadherence, regimen modifications, and healthcare utilization and expenditures. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 36-41.	2.2	10
33	Quality of Psychopharmacological Medication Prescribing and Mortality in Medicare Beneficiaries in Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1490-1504.	2.6	20
34	Antiparkinson Drug Adherence and Its Association with Health Care Utilization and Economic Outcomes in a Medicare Part D Population. <i>Value in Health</i> , 2014, 17, 196-204.	0.3	24
35	Quality of psychopharmacological medication use in nursing home residents. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, 494-507.	3.0	30
36	O4-13-04: ANTIPSYCHOTICS AND OTHER PSYCHOPHARMACOLOGICAL MEDICATION USE IN UNITED STATES NURSING HOMES: WHAT ARE THE CONCERNS AND ACTIONS TAKING PLACE TO OPTIMIZE PRESCRIBING?. , 2014, 10, P278-P279.		0

#	ARTICLE	IF	CITATIONS
37	Antiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson's Disease. <i>Clinical Therapeutics</i> , 2013, 35, 1513-1525.e1.	2.5	27
38	Association of Chronic Obstructive Pulmonary Disease Maintenance Medication Adherence With All-Cause Hospitalization and Spending in a Medicare Population. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 201-210.	3.0	102
39	Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 384-394.	3.0	14